Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors

ÖZOĞUL, Ece; KÖSEMEHMETOĞLU, Kemal

Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors

Kemal KÖSEMEHMETOĞLU, (Hacettepe University, Faculty of Medici)

Ece ÖZOĞUL (Hacettepe University, Faculty of Medici)

Türk Patoloji Dergisi

2 1

Yıl: 2017 Cilt: 33 Sayı: 3 Sayfa Aralığı: 192 - 197 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors

Öz:

Objective: Programmed death ligand 1 (PD-L1) found on tumor cells has recently been reported to have a key role in the development and dissemination of many tumors, such as lung and breast carcinomas. In this study, we retrospectively analyzed PD-L1 expression among different types of sarcomas.Material and Method: Tissue microarrays of 3-4 mm diameter were composed from paraffin blocks of 222 various sarcomas. Slides prepared from microarrays were stained for PD-L1 antibody (Cell Signaling, e1L3n®) using Leica Bond Autostainer. Any membranous staining over 5% of the cells was regarded as positive. Quantitative real-time PCr with TaqMan gene expression assays for PDL1 was performed using whole sections from FFPe tissue of PD-L1 positive cases, by normalizing absolute values to β-actin. relative expression level of mrnA of PDL1 was calculated and scored using Log102(threshold cycle of b-actin - threshold cycle of PDL1).Results: Immunohistochemically, PD-L1 expression was present in 34 of 222 (15%) sarcomas. 5/13 (39%) undifferentiated pleomorphic sarcomas, 6/18 (33%) malignant peripheral nerve sheath tumors, 5/16 (31%) dedifferentiated liposarcomas, 4/19 (21%) rhabdomyosarcomas, 2/16 (13%) epithelioid sarcomas, 2/15 (13%) leiomyosarcomas, 3/26 (12%) synovial sarcomas, 1/18 (6%) myxoid liposarcoma, 1/2 (50%) extraskeletal myxoid chondrosarcoma, 1/3 (33%) alveolar soft part sarcoma, 1/3 (33%) parachordoma/myoepithelioma, 1/5 (20%) pleomorphic liposarcoma, 1/7 (14%) angiosarcoma, 1/8 (13%) ewing sarcoma showed PD-L1 expression. Cases of solitary fibrous tumor/hemangiopericytoma (18), desmoplastic round cell tumor (14), ewing-like sarcoma (6), epithelioid hemangioendothelioma (5), clear cell sarcoma (4), myxofibrosarcoma (4), low grade fibromyxoid sarcoma (2) were all negative. Tumor-infiltrating hematopoietic cells were positive for PD-L1 in 32 cases (15%) with only 2 cases overlapping with PD-L1 staining in tumoral cells. Sixteen of 34 (47%) immunohistochemically PD-L1 positive cases showed significant but low-level PD-L1 mrnA overexpression.Conclusion: We have shown PD-L1 expression in a subset of sarcomas, both at the protein and mrnA level. High-grade pleomorphic sarcomas tend to show more frequent PD-L1 expression. Clinical trials are necessary to further assess the effect of anti PD-L1 drugs on sarcomas showing PD-L1 expression

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945-54.
2. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PDL1). J Thorac Oncol. 2013;8:803-5.
3. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107-16.
4. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104:3360-5.
5. Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: Perspectives and issues. Int J Clin Oncol. 2016;21:462-73
6. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-9.
7. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2:690-8.
8. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, Kang MJ, Jang KY. Tumor infiltrating PD1-positive lymphocytes and the expression of PDL1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870.
9. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. Prognostic implications of PDL1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16:434.
10. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46-54.
11. Inaguma S, Wang Z, Lasota J, Sarlomo-Rikala M, McCue PA, Ikeda H, Miettinen M. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): Analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol. 2016;40:1133-42.
12. D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357-65.
13. Matthew S, Mackinnon AC. Programmed Death-Ligand 1 expression in sarcomas, a clinical a pathologic study [abstract]. Modern Pathology. 2016;29 (suppl 2):22A-23A.
14. Paydas S, Bagir EK, Deveci MA, Gonlusen G. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol. 2016;33:93.
15. Shurell E, Singh AS, Crompton JG, Jensen S, Li Y, Dry S, Nelson S, Chmielowski B, Bernthal N, Federman N, Tumeh P, Eilber FC. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget. 2016;7:64300-8.
16. Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y, Fujishita T, Maehara Y. PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer. J Thorac Oncol. 2016;11:62-71.

APA	KÖSEMEHMETOĞLU K, ÖZOĞUL E (2017). Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. , 192 - 197.
Chicago	KÖSEMEHMETOĞLU Kemal,ÖZOĞUL Ece Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. (2017): 192 - 197.
MLA	KÖSEMEHMETOĞLU Kemal,ÖZOĞUL Ece Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. , 2017, ss.192 - 197.
AMA	KÖSEMEHMETOĞLU K,ÖZOĞUL E Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. . 2017; 192 - 197.
Vancouver	KÖSEMEHMETOĞLU K,ÖZOĞUL E Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. . 2017; 192 - 197.
IEEE	KÖSEMEHMETOĞLU K,ÖZOĞUL E "Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors." , ss.192 - 197, 2017.
ISNAD	KÖSEMEHMETOĞLU, Kemal - ÖZOĞUL, Ece. "Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors". (2017), 192-197.

APA	KÖSEMEHMETOĞLU K, ÖZOĞUL E (2017). Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. Türk Patoloji Dergisi, 33(3), 192 - 197.
Chicago	KÖSEMEHMETOĞLU Kemal,ÖZOĞUL Ece Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. Türk Patoloji Dergisi 33, no.3 (2017): 192 - 197.
MLA	KÖSEMEHMETOĞLU Kemal,ÖZOĞUL Ece Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. Türk Patoloji Dergisi, vol.33, no.3, 2017, ss.192 - 197.
AMA	KÖSEMEHMETOĞLU K,ÖZOĞUL E Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. Türk Patoloji Dergisi. 2017; 33(3): 192 - 197.
Vancouver	KÖSEMEHMETOĞLU K,ÖZOĞUL E Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. Türk Patoloji Dergisi. 2017; 33(3): 192 - 197.
IEEE	KÖSEMEHMETOĞLU K,ÖZOĞUL E "Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors." Türk Patoloji Dergisi, 33, ss.192 - 197, 2017.
ISNAD	KÖSEMEHMETOĞLU, Kemal - ÖZOĞUL, Ece. "Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors". Türk Patoloji Dergisi 33/3 (2017), 192-197.